Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9652 |
High Similarity |
NPD1610 |
Phase 2 |
0.9646 |
High Similarity |
NPD1548 |
Phase 1 |
0.9098 |
High Similarity |
NPD4908 |
Phase 1 |
0.896 |
High Similarity |
NPD1613 |
Approved |
0.896 |
High Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.8952 |
High Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.879 |
High Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.871 |
High Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.856 |
High Similarity |
NPD2861 |
Phase 2 |
0.855 |
High Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.855 |
High Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.8525 |
High Similarity |
NPD422 |
Phase 1 |
0.8485 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.8425 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.8387 |
Intermediate Similarity |
NPD4749 |
Approved |
0.8261 |
Intermediate Similarity |
NPD968 |
Approved |
0.8217 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.8217 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.8175 |
Intermediate Similarity |
NPD7212 |
Phase 2 |
0.8175 |
Intermediate Similarity |
NPD7213 |
Phase 3 |
0.814 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.808 |
Intermediate Similarity |
NPD1091 |
Approved |
0.807 |
Intermediate Similarity |
NPD940 |
Approved |
0.807 |
Intermediate Similarity |
NPD846 |
Approved |
0.8034 |
Intermediate Similarity |
NPD290 |
Approved |
0.803 |
Intermediate Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.803 |
Intermediate Similarity |
NPD5124 |
Phase 1 |
0.7986 |
Intermediate Similarity |
NPD7447 |
Phase 1 |
0.7985 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.7955 |
Intermediate Similarity |
NPD1240 |
Approved |
0.7836 |
Intermediate Similarity |
NPD1607 |
Approved |
0.7826 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7826 |
Intermediate Similarity |
NPD1242 |
Phase 1 |
0.7815 |
Intermediate Similarity |
NPD2684 |
Approved |
0.7812 |
Intermediate Similarity |
NPD6583 |
Phase 3 |
0.7812 |
Intermediate Similarity |
NPD6582 |
Phase 2 |
0.7805 |
Intermediate Similarity |
NPD6671 |
Approved |
0.7794 |
Intermediate Similarity |
NPD2796 |
Approved |
0.7754 |
Intermediate Similarity |
NPD1652 |
Phase 2 |
0.773 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7724 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7671 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7664 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.7664 |
Intermediate Similarity |
NPD6099 |
Approved |
0.7664 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7655 |
Intermediate Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.7638 |
Intermediate Similarity |
NPD6516 |
Phase 2 |
0.7638 |
Intermediate Similarity |
NPD5846 |
Approved |
0.7634 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7634 |
Intermediate Similarity |
NPD6584 |
Phase 3 |
0.7626 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7619 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.7615 |
Intermediate Similarity |
NPD3225 |
Approved |
0.7591 |
Intermediate Similarity |
NPD7033 |
Discontinued |
0.7586 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7571 |
Intermediate Similarity |
NPD7466 |
Approved |
0.7561 |
Intermediate Similarity |
NPD7843 |
Approved |
0.7561 |
Intermediate Similarity |
NPD821 |
Approved |
0.7561 |
Intermediate Similarity |
NPD5535 |
Approved |
0.7557 |
Intermediate Similarity |
NPD2797 |
Approved |
0.7537 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.7535 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7534 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.7519 |
Intermediate Similarity |
NPD1547 |
Clinical (unspecified phase) |
0.7518 |
Intermediate Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.7518 |
Intermediate Similarity |
NPD4538 |
Approved |
0.7518 |
Intermediate Similarity |
NPD4536 |
Approved |
0.7517 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7517 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.7483 |
Intermediate Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.7481 |
Intermediate Similarity |
NPD8651 |
Approved |
0.748 |
Intermediate Similarity |
NPD1894 |
Discontinued |
0.7478 |
Intermediate Similarity |
NPD2859 |
Approved |
0.7478 |
Intermediate Similarity |
NPD2860 |
Approved |
0.7464 |
Intermediate Similarity |
NPD5588 |
Approved |
0.7464 |
Intermediate Similarity |
NPD5960 |
Phase 3 |
0.7464 |
Intermediate Similarity |
NPD3748 |
Approved |
0.7459 |
Intermediate Similarity |
NPD5451 |
Approved |
0.745 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7448 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7447 |
Intermediate Similarity |
NPD3892 |
Phase 2 |
0.7444 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.7432 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.7431 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7426 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7407 |
Intermediate Similarity |
NPD1296 |
Phase 2 |
0.7405 |
Intermediate Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.7391 |
Intermediate Similarity |
NPD2200 |
Suspended |
0.7391 |
Intermediate Similarity |
NPD2933 |
Approved |
0.7391 |
Intermediate Similarity |
NPD2934 |
Approved |
0.7388 |
Intermediate Similarity |
NPD1008 |
Clinical (unspecified phase) |
0.7385 |
Intermediate Similarity |
NPD1535 |
Discovery |
0.7381 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7381 |
Intermediate Similarity |
NPD2557 |
Approved |
0.7376 |
Intermediate Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.7361 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7344 |
Intermediate Similarity |
NPD6580 |
Approved |
0.7344 |
Intermediate Similarity |
NPD6581 |
Approved |
0.7339 |
Intermediate Similarity |
NPD228 |
Approved |
0.7338 |
Intermediate Similarity |
NPD3846 |
Clinical (unspecified phase) |
0.7333 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.7328 |
Intermediate Similarity |
NPD1608 |
Approved |
0.7328 |
Intermediate Similarity |
NPD1481 |
Phase 2 |
0.7324 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.7323 |
Intermediate Similarity |
NPD3596 |
Phase 2 |
0.7319 |
Intermediate Similarity |
NPD3052 |
Approved |
0.7319 |
Intermediate Similarity |
NPD3054 |
Approved |
0.7317 |
Intermediate Similarity |
NPD4750 |
Phase 3 |
0.7315 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7293 |
Intermediate Similarity |
NPD1203 |
Approved |
0.7292 |
Intermediate Similarity |
NPD6799 |
Approved |
0.7288 |
Intermediate Similarity |
NPD3020 |
Approved |
0.7287 |
Intermediate Similarity |
NPD6830 |
Clinical (unspecified phase) |
0.7279 |
Intermediate Similarity |
NPD8158 |
Clinical (unspecified phase) |
0.7279 |
Intermediate Similarity |
NPD3268 |
Approved |
0.7273 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.7273 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.7266 |
Intermediate Similarity |
NPD4978 |
Clinical (unspecified phase) |
0.726 |
Intermediate Similarity |
NPD5403 |
Approved |
0.7248 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.7246 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7246 |
Intermediate Similarity |
NPD4340 |
Discontinued |
0.7241 |
Intermediate Similarity |
NPD5401 |
Approved |
0.7239 |
Intermediate Similarity |
NPD3691 |
Phase 2 |
0.7239 |
Intermediate Similarity |
NPD3690 |
Phase 2 |
0.7231 |
Intermediate Similarity |
NPD1778 |
Approved |
0.7226 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7226 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7226 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7226 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7222 |
Intermediate Similarity |
NPD1241 |
Discontinued |
0.7222 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.7209 |
Intermediate Similarity |
NPD1182 |
Approved |
0.72 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7197 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.7197 |
Intermediate Similarity |
NPD2235 |
Phase 2 |
0.7197 |
Intermediate Similarity |
NPD2231 |
Phase 2 |
0.7183 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.7174 |
Intermediate Similarity |
NPD2238 |
Phase 2 |
0.7174 |
Intermediate Similarity |
NPD1558 |
Phase 1 |
0.7174 |
Intermediate Similarity |
NPD5837 |
Clinical (unspecified phase) |
0.7171 |
Intermediate Similarity |
NPD3749 |
Approved |
0.7154 |
Intermediate Similarity |
NPD3444 |
Approved |
0.7154 |
Intermediate Similarity |
NPD3443 |
Approved |
0.7154 |
Intermediate Similarity |
NPD3445 |
Approved |
0.7154 |
Intermediate Similarity |
NPD3049 |
Approved |
0.7143 |
Intermediate Similarity |
NPD5327 |
Phase 3 |
0.7143 |
Intermediate Similarity |
NPD7097 |
Phase 1 |
0.7143 |
Intermediate Similarity |
NPD3685 |
Discontinued |
0.7143 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.7131 |
Intermediate Similarity |
NPD9697 |
Approved |
0.7122 |
Intermediate Similarity |
NPD5735 |
Approved |
0.7115 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.7114 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.7113 |
Intermediate Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.7105 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7103 |
Intermediate Similarity |
NPD6666 |
Approved |
0.7103 |
Intermediate Similarity |
NPD6667 |
Approved |
0.7101 |
Intermediate Similarity |
NPD7477 |
Discontinued |
0.7099 |
Intermediate Similarity |
NPD17 |
Approved |
0.7099 |
Intermediate Similarity |
NPD2556 |
Approved |
0.7099 |
Intermediate Similarity |
NPD5238 |
Clinical (unspecified phase) |
0.7099 |
Intermediate Similarity |
NPD2554 |
Approved |
0.709 |
Intermediate Similarity |
NPD7258 |
Clinical (unspecified phase) |
0.709 |
Intermediate Similarity |
NPD6696 |
Suspended |
0.7089 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.7087 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.7086 |
Intermediate Similarity |
NPD7046 |
Clinical (unspecified phase) |
0.7083 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.708 |
Intermediate Similarity |
NPD6179 |
Discontinued |
0.7068 |
Intermediate Similarity |
NPD1840 |
Phase 2 |
0.7063 |
Intermediate Similarity |
NPD2424 |
Discontinued |
0.705 |
Intermediate Similarity |
NPD4140 |
Approved |
0.7045 |
Intermediate Similarity |
NPD3496 |
Discontinued |
0.7045 |
Intermediate Similarity |
NPD3847 |
Discontinued |
0.7044 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7037 |
Intermediate Similarity |
NPD3267 |
Approved |
0.7037 |
Intermediate Similarity |
NPD3266 |
Approved |
0.7029 |
Intermediate Similarity |
NPD3056 |
Clinical (unspecified phase) |
0.7025 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7023 |
Intermediate Similarity |
NPD6382 |
Discontinued |
0.7015 |
Intermediate Similarity |
NPD6542 |
Approved |
0.7015 |
Intermediate Similarity |
NPD6540 |
Phase 3 |
0.7015 |
Intermediate Similarity |
NPD6539 |
Approved |
0.7015 |
Intermediate Similarity |
NPD6543 |
Approved |
0.6986 |
Remote Similarity |
NPD643 |
Clinical (unspecified phase) |
0.6986 |
Remote Similarity |
NPD6815 |
Approved |
0.6983 |
Remote Similarity |
NPD9365 |
Approved |
0.6981 |
Remote Similarity |
NPD7054 |
Approved |
0.6981 |
Remote Similarity |
NPD5844 |
Phase 1 |
0.6978 |
Remote Similarity |
NPD6405 |
Approved |
0.6978 |
Remote Similarity |
NPD4062 |
Phase 3 |
0.6978 |
Remote Similarity |
NPD6407 |
Approved |
0.6977 |
Remote Similarity |
NPD709 |
Approved |
0.6974 |
Remote Similarity |
NPD1465 |
Phase 2 |
0.6974 |
Remote Similarity |
NPD8455 |
Phase 2 |
0.6972 |
Remote Similarity |
NPD4308 |
Phase 3 |
0.697 |
Remote Similarity |
NPD2668 |
Approved |
0.697 |
Remote Similarity |
NPD4626 |
Approved |
0.697
|
Remote Similarity |
NPD2667 |
Approved |